Vascular Biogenics (NASDAQ:VBLT) Earns “Hold” Rating from Chardan Capital

Vascular Biogenics (NASDAQ:VBLT)‘s stock had its “hold” rating reiterated by research analysts at Chardan Capital in a research note issued to investors on Tuesday, AnalystRatings.com reports. They presently have a $3.00 price target on the biopharmaceutical company’s stock. Chardan Capital’s target price would indicate a potential upside of 152.10% from the stock’s current price.

A number of other brokerages also recently issued reports on VBLT. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Vascular Biogenics in a research report on Thursday, May 16th. Oppenheimer initiated coverage on shares of Vascular Biogenics in a research report on Thursday, June 27th. They issued an “outperform” rating and a $2.00 price objective for the company. CIBC initiated coverage on shares of Vascular Biogenics in a research report on Thursday, June 27th. They issued an “outperform” rating for the company. Zacks Investment Research downgraded shares of Vascular Biogenics from a “buy” rating to a “hold” rating in a research report on Thursday, May 30th. Finally, ValuEngine raised shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Vascular Biogenics presently has an average rating of “Buy” and an average price target of $2.38.

VBLT stock traded down $0.01 during trading on Tuesday, reaching $1.19. The stock had a trading volume of 17,356 shares, compared to its average volume of 36,611. Vascular Biogenics has a one year low of $0.60 and a one year high of $1.90. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.35 and a quick ratio of 8.35. The stock has a 50 day moving average price of $1.30. The stock has a market cap of $45.21 million, a P/E ratio of -1.92 and a beta of -0.33.

Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.06). Vascular Biogenics had a negative return on equity of 31.69% and a negative net margin of 2,724.02%. The firm had revenue of $0.22 million during the quarter, compared to the consensus estimate of $2.30 million. Equities research analysts anticipate that Vascular Biogenics will post -0.53 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VBLT. Athena Capital Advisors LLC purchased a new position in Vascular Biogenics in the first quarter valued at about $25,000. Menta Capital LLC purchased a new position in Vascular Biogenics in the first quarter valued at about $35,000. Finally, First Republic Investment Management Inc. boosted its stake in Vascular Biogenics by 7.4% in the first quarter. First Republic Investment Management Inc. now owns 145,000 shares of the biopharmaceutical company’s stock valued at $220,000 after acquiring an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 6.80% of the company’s stock.

About Vascular Biogenics

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Featured Article: How to Invest in a Bull Market

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.